Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial
COVID-19 represents a global crisis. Rapidly conducting a clinical trial with the rigor necessary to obtain reliable results requires the collaboration of various participants involved in the development, evaluation and authorization of clinical trials (CT) such as the trial sponsor, researchers, regulatory authority and the ethics committee (EC). Carrying out these studies is not only scientifically appropriate, but an ethical and moral obligation to guarantee our patients effective treatment. SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy. Peru has joined the list of countries where the trial will be reproduced, through which it will be possible to quickly identify if any of these drugs offers a real benefit to patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Revista Peruana de Medicina Experimental y Salud Pública - 37(2020), 2, Seite 356-60 |
| Sprache: |
Spanisch |
|---|
| Beteiligte Personen: |
Alonso Soto [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| doi: |
10.17843/rpmesp.2020.372.5546 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ013383140 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ013383140 | ||
| 003 | DE-627 | ||
| 005 | 20230310054353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2020 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.17843/rpmesp.2020.372.5546 |2 doi | |
| 035 | |a (DE-627)DOAJ013383140 | ||
| 035 | |a (DE-599)DOAJfa2b99836fc442d68f5067d9cb9e08d8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 050 | 0 | |a R5-920 | |
| 100 | 0 | |a Alonso Soto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid responses to the COVID-19 through science and global collaboration: the solidarity clinical trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a COVID-19 represents a global crisis. Rapidly conducting a clinical trial with the rigor necessary to obtain reliable results requires the collaboration of various participants involved in the development, evaluation and authorization of clinical trials (CT) such as the trial sponsor, researchers, regulatory authority and the ethics committee (EC). Carrying out these studies is not only scientifically appropriate, but an ethical and moral obligation to guarantee our patients effective treatment. SOLIDARITY is a mega clinical trial that recruited thousands of subjects with moderate to severe disease, who were randomly assigned to one of the treatment groups under evaluation, including hydroxychloroquine, lopinavir/ritonavir associated or not with interferon; or remdesivir compared to standard therapy. Peru has joined the list of countries where the trial will be reproduced, through which it will be possible to quickly identify if any of these drugs offers a real benefit to patients | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a ensayos clínicos | |
| 650 | 4 | |a hidroxicloroquina | |
| 650 | 4 | |a remdesivir | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 653 | 0 | |a Medicine (General) | |
| 700 | 0 | |a Dante M. Quiñones-Laveriano |e verfasserin |4 aut | |
| 700 | 0 | |a Patricia J. García |e verfasserin |4 aut | |
| 700 | 0 | |a Eduardo Gotuzzo |e verfasserin |4 aut | |
| 700 | 0 | |a Ana María Henao-Restrepo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Revista Peruana de Medicina Experimental y Salud Pública |d Instituto Nacional de Salud, 2009 |g 37(2020), 2, Seite 356-60 |w (DE-627)DOAJ000042609 |x 17264642 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:2 |g pages:356-60 |
| 856 | 4 | 0 | |u https://doi.org/10.17843/rpmesp.2020.372.5546 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fa2b99836fc442d68f5067d9cb9e08d8 |z kostenfrei |
| 856 | 4 | 0 | |u https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5546 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1726-4634 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1726-4642 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 2 |h 356-60 | ||